All Stories

ASCO: Immatics PRAME cell therapy tied to 56% response rate in melanoma study

Immatics’ cell therapy has been linked to a 56% objective response rate among 32 heavily pretreated patients with metastatic melanoma.

May 31, 2025 - 13:30
 0
ASCO: Immatics PRAME cell therapy tied to 56% response rate in melanoma study
Immatics’ cell therapy has been linked to a 56% objective response rate among 32 heavily pretreated patients with metastatic melanoma.
Read More

Tags:

Previous Article

Flight Attendant Caught Smuggling 100 Pounds of Deadly Drug Made From Human Bone...

Next Article

At ASCO, Enhertu cements growing role in stomach cancer care

Related Posts

Prothena reburies drug after 2nd swing at rare disease misses, plans 'substantial' layoffs

Prothena reburies drug after 2nd swing at rare disease ...

May 27, 2025  0

Blueprint revises $1.67B VantAI pact again, zeroing in on molecular glue potential

Blueprint revises $1.67B VantAI pact again, zeroing in ...

May 21, 2025  0

Alpheus Medical nets $52M to trial ultrasound-activated brain tumor therapy

Alpheus Medical nets $52M to trial ultrasound-activated...

May 16, 2025  0